Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.
about
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Direct antitumour activity of zoledronic acid: preclinical and clinical data.How do bisphosphonates inhibit bone metastasis in vivo?Oral bisphosphonate use and breast cancer incidence in postmenopausal women.Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic PerspectivesExtracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells.VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro.Jaw osteonecrosis in patients treated with bisphosphonates: an ultrastructural study.
P2860
Q33739204-A9B200F4-ED26-47C1-A6D5-C56126196285Q33850938-05115BE4-2694-41F8-B86C-3DDAE5D9DDBFQ34009853-97869D2F-6216-48A8-9E2C-2FAF210C57C8Q34049239-6531D299-F161-4D0E-A3AD-58787CC97DF1Q34122791-572E975F-7997-40AB-ADDD-90608F5F8A1CQ34145863-FAD7239E-0A2A-42B2-B482-B750A012F60EQ34480630-91446F72-8F00-4B6E-B38A-36CEAEB3AF74Q35259094-54DE37AB-3CA1-41E0-8D39-C9635FB835EAQ35667318-80AD535E-2D63-43AB-8BEF-529F2EEFBF95Q36643023-83E89925-F9CA-4E4D-A2C7-0B77134BEB2FQ37321938-474F8430-4A36-43A5-8516-D76F53AE196CQ37441608-0243092F-2CC6-4CA4-8B82-8AAA337B715EQ37460998-6925E8C1-5A2C-4535-AC34-419EB153851CQ39774289-FD25E24A-3135-43D0-A2FC-DFB3B213F8E2Q40143407-156556D3-C248-4E4F-9DD3-F48D7021B9CDQ51626904-906509CC-F2B3-44F0-888B-F74B4F07DC25
P2860
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Bisphosphonates antagonise bon ...... breast cancer cells survival.
@ast
Bisphosphonates antagonise bon ...... breast cancer cells survival.
@en
type
label
Bisphosphonates antagonise bon ...... breast cancer cells survival.
@ast
Bisphosphonates antagonise bon ...... breast cancer cells survival.
@en
prefLabel
Bisphosphonates antagonise bon ...... breast cancer cells survival.
@ast
Bisphosphonates antagonise bon ...... breast cancer cells survival.
@en
P2093
P2860
P356
P1476
Bisphosphonates antagonise bon ...... breast cancer cells survival.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601009
P407
P577
2003-07-01T00:00:00Z